Moderna to onshore drug product manufacturing to Massachusetts

Core Insights - Moderna is expanding its US manufacturing capabilities by investing over $140 million to onshore drug product manufacturing to its existing Moderna Technology Center in Norwood, Massachusetts [1][3] - This initiative aims to establish a comprehensive manufacturing platform for mRNA therapies and vaccines, enhancing the company's infrastructure in the US [2][4] - The construction of the new facility has begun, with completion expected in the first half of 2027, and it will create several skilled biomanufacturing jobs [3][4] Investment and Strategic Goals - The investment is part of Moderna's ongoing commitment to US-based infrastructure, supporting both commercial and clinical supply of mRNA medicines [1][2] - Since its partnership with the US government through Operation Warp Speed, Moderna has been at the forefront of biomedical innovation across various disease areas [2] - The company received $590 million in funding from the US Department of Health and Human Services in 2025 to expedite the development of mRNA-based pandemic influenza vaccines, further enhancing national preparedness for infectious diseases [4]